San Francisco, May 19, 2021 – Recardio Inc., a clinical-stage life science company focusing on regenerative therapies for cardiovascular diseases, announced the completion of its Phase 2, Randomized, Double-Blind, Placebo-Controlled, Safety and Efficacy Study of Dutogliptin in Combination with Filgrastim in Early Recovery Post-Myocardial Infarction.

Read More

San Francisco, April 26, 2021 – Recardio Inc., a clinical-stage life science company focusing on regenerative therapies for cardiovascular and other diseases, announced today that it is participating in the BIO Digital 2021 (BIO International Convention).

Read More

San Francisco, December 17, 2020 – Recardio Inc., a life science company developing regenerative therapies for cardiovascular diseases, announced that its positive results of the interim analysis of Recardio’s Phase 2 clinical trial in AMI were published in the latest release of the European Heart Journal. The current version of the journal relates to the presentation during the 2020 Congress of the European Society of Cardiology.

Read More

San Francisco, September 14, 2020 – Recardio Inc., a life science company developing regenerative therapies for cardiovascular diseases, announced publication of the study protocol for its Clinical Phase 2 Study. Entitled “Protocol for a phase 2, randomized, double-blind, placebo-controlled, safety and efficacy study of dutogliptin in combination with filgrastim in early recovery post-myocardial infarction”, the article can be accessed here: https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-020-04652-0

Read More

San Francisco, June 29, 2020 – Recardio Inc., a life science company developing regenerative therapies for cardiovascular diseases, announced that the results of the interim analysis of Recardio’s Phase 2 clinical trial will be presented at the 2020 Congress of the European Society of Cardiology from August 29th through September 1st.

Read More